

**Abemaciclib**

## Section

Targeted therapies

## Indications

Therapeutic equivalent to [palbociclib](#) for

Other specified malignant neoplasms of breast

**Afatinib**

## Section

Targeted therapies

## Indications

Therapeutic equivalent to [erlotinib](#) for

Other specified malignant neoplasms of bronchus or lung

**All-trans retinoic acid**

## Section

Targeted therapies

Oral &gt; Solid: 10 mg capsule

## Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

**Binimetinib**

## Section

Targeted therapies

## Indications

Therapeutic equivalent to [trametinib](#) for

Other specified melanoma of skin

**Bortezomib**

## Section

Targeted therapies

Parenteral &gt; General injections &gt; unspecified: 3.5 mg in vial powder for injection

## Indications

Plasma cell myeloma

**Cobimetinib**

## Section

Targeted therapies

## Indications

Therapeutic equivalent to [trametinib](#) for

Other specified melanoma of skin

## Crizotinib

### Section

#### Targeted therapies

Oral > Solid: 200 mg; 250 mg

Oral > Solid > capsule: 200 mg; 250 mg

### Indications

Other specified malignant neoplasms of bronchus or lung

Anaplastic large cell lymphoma, ALK-positive

## Dabrafenib

### Section

#### Targeted therapies

Oral > Solid: 50 mg; 75 mg

### Indications

Other specified melanoma of skin

## Dasatinib

### Section

#### Targeted therapies

Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet

### Indications

Chronic myeloid leukaemia, not elsewhere classified

## Encorafenib

### Section

#### Targeted therapies

### Indications

Therapeutic equivalent to dabrafenib for

Other specified melanoma of skin

## Erlotinib

### Section

#### Targeted therapies

Oral > Solid: 100 mg; 150 mg

### Indications

Other specified malignant neoplasms of bronchus or lung

## Everolimus

### Section

#### Targeted therapies

Oral > Solid > dispersible tablet: 2 mg; 3 mg; 5 mg

Oral > Solid > tablet: 2.5 mg; 5 mg; 7.5 mg; 10 mg

### Indications

Other specified gliomas of brain

## Gefitinib

### Section

Targeted therapies

### Indications

Therapeutic equivalent to erlotinib for

Other specified malignant neoplasms of bronchus or lung

## Ibrutinib

### Section

Targeted therapies

Oral > Solid: 140 mg

### Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

## Imatinib

### Section

Targeted therapies

Oral > Solid: 100 mg; 400 mg

### Indications

B lymphoblastic leukaemia or lymphoma with t(9:22) (q34;q11.2); BCR-ABL1

Gastrointestinal stromal tumour of unspecified gastrointestinal sites

Chronic myeloid leukaemia, not elsewhere classified

## Nilotinib

### Section

Targeted therapies

Oral > Solid > capsule: 150 mg; 200 mg

### Indications

Chronic myeloid leukaemia, not elsewhere classified

## Osimertinib

### Section

Targeted therapies

Oral > Solid: 40 mg (as mesylate); 80 mg (as mesylate)

### Indications

Other specified malignant neoplasms of bronchus or lung

## Palbociclib

### Section

Targeted therapies

Oral > Solid: 75 mg; 100 mg; 125 mg

### Indications

Other specified malignant neoplasms of breast

## Pertuzumab

### Section

#### Targeted therapies

Parenteral > General injections > IV: 240 mg per 14 mL in vial concentrated solution

### Indications

Carcinoma of breast, specialised type

## Ribociclib

### Section

#### Targeted therapies

### Indications

Therapeutic equivalent to [palbociclib](#) for

Other specified malignant neoplasms of breast

## Rituximab

### Section

#### Targeted therapies

Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial

### Indications

Follicular lymphoma

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Diffuse large B-cell lymphomas

Burkitt lymphoma including Burkitt leukaemia

## Trametinib

### Section

#### Targeted therapies

Oral > Solid: 0.5 mg; 2 mg

### Indications

Other specified melanoma of skin

## Trastuzumab

### Section

#### Targeted therapies

Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection

### Indications

Carcinoma of breast, specialised type

## Trastuzumab emtansine

### Section

#### Targeted therapies

Parenteral > General injections > IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection

### Indications

Carcinoma of breast, specialised type

## Vemurafenib

### Section

Targeted therapies

### Indications

Therapeutic equivalent to dabrafenib for

Other specified melanoma of skin

## Zanubrutinib

### Section

Targeted therapies

Oral > Solid: 80 mg

### Indications

Mantle cell lymphoma

Chronic lymphocytic leukaemia or small lymphocytic lymphoma